Association between intestinal flora and secondary resistance to imatinib in gastrointestinal stromal tumors
10.11855/j.issn.0577-7402.0056.2024.0620
- VernacularTitle:肠道菌群与胃肠道间质瘤伊马替尼继发耐药的关系研究进展
- Author:
Hao-Lin LI
1
;
Shu WANG
;
Yan ZHAO
;
Jian-Jun YANG
Author Information
1. 空军军医大学第一附属医院/西京消化病医院消化外科,陕西 西安 710032;空军军医大学西京消化病医院消化系肿瘤整合防治全国重点实验室,陕西 西安 710032;空军军医大学基础医学院学员五大队,陕西 西安 710032
- Keywords:
gastrointestinal stromal tumor;
gastrointestinal microbiome;
imatinib mesylate;
drug resistance
- From:
Medical Journal of Chinese People's Liberation Army
2025;50(3):277-283
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumor(GIST)is the most prevalent mesenchymal tumor of the gastrointestinal tract,with imatinib serving as the first-line drug for metastatic GIST due to its good clinical efficacy.However,the majority of patients exhibit tumor progression within several years of drug therapy,primarily due to the high rate of drug resistance,which significantly impedes drug therapeutic outcome and patient prognosis.Traditional approaches to counteract resistance,including dosage increase and subsequent line therapy yielded suboptimal results.As a research hotspot,intestinal flora has been proven to be closely related to drug resistance of various tumors.In recent years,it has been observed that specific intestinal flora could serve as biomarkers for early GIST patient screening or as potential drug targets,and modulating the intestinal flora through interventions may delay or even reverse the progression of imatinib secondary drug resistance in GIST.This review delineates the drug resistance of GIST,correlations between intestinal flora and drug resistance of tumors,as well as the relationship between intestinal flora and drug resistance of GIST,aiming to provide novel perspectives and methodologies for clinical application.
